Data gathered: May 17
Alternative Data for Bio-Rad
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 160 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 588,000 | Sign up | Sign up | Sign up |
| Employee Rating | 71 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 481 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 140 | Sign up | Sign up | Sign up |
| Facebook Followers | 9,427 | Sign up | Sign up | Sign up |
| Instagram Followers | 11,251 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 966 | Sign up | Sign up | Sign up |
| Twitter Followers | 17,213 | Sign up | Sign up | Sign up |
| Twitter Mentions | 159 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 55 | Sign up | Sign up | Sign up |
| Linkedin Employees | 8,622 | Sign up | Sign up | Sign up |
About Bio-Rad
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market.
| Price | $295.73 |
| Target Price | Sign up |
| Volume | 224,250 |
| Market Cap | $8.31B |
| Year Range | $268.26 - $376.23 |
| Dividend Yield | 0% |
| PE Ratio | 31.53 |
| Revenue per Employee | $313,655 |
| Industry | Biotechnology |
In the news
Global Flow Cytometry Market Report 2024-2029, Featuring Agilent Technologies, BD, Bio-Rad Laboratories, Cytek Biosciences, Danaher, Miltenyi Biotec, Sony Biotechnology and Standard BiotoolsMay 15 - GlobeNewswire |
|
 |
Jump Financial LLC Purchases Shares of 5,163 Bio-Rad Laboratories, Inc. (NYSE:BIO)May 15 - ETF Daily News |
|
Bio-Rad Laboratories (NYSE:BIO) Rating Lowered to Hold at StockNews.comMay 14 - ETF Daily News |
|
Metis Global Partners LLC Trims Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)May 12 - ETF Daily News |
 |
UBS Group Cuts Bio-Rad Laboratories (NYSE:BIO) Price Target to $385.00May 12 - ETF Daily News |
|
National Bank of Canada FI Cuts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)May 11 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '24 | 600M | 542M | 326M | 384M | 546M | 2.290 |
| Q4 '23 | 681M | 420M | 366M | 350M | 338M | 3.100 |
| Q3 '23 | 621M | 504M | 336M | 106M | 156M | 2.330 |
| Q2 '23 | 669M | 532M | 363M | -1.16B | -1.48B | 3.000 |
| Q1 '23 | 666M | 582M | 362M | 69M | 139M | 3.340 |
Insider Transactions View All
| ERNST TIMOTHY S filed to sell 3,397 shares at $330.6. February 29 '24 |
| Crowley Michael filed to sell 6,942 shares at $336. February 28 '24 |
| WRIGHT DARA filed to sell 1,499 shares at $299.2. December 12 '23 |
| Crowley Michael filed to sell 6,942 shares at $305.1. November 28 '23 |
| ERNST TIMOTHY S filed to sell 2,416 shares at $396.4. August 31 '23 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
| Rohit Khanna Democrat |
Nov 8, 23 | Sell | $15K - $50K |
| Lois Frankel Democrat |
Oct 10, 23 | Sell | $1K - $15K |
Read more about Bio-Rad (BIO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Bio-Rad?
The Market Cap of Bio-Rad is $8.31B.
What is Bio-Rad's PE Ratio?
As of today, Bio-Rad's PE (Price to Earnings) ratio is 31.53.
How Many People Work at Bio-Rad?
As of our latest update, Bio-Rad employed approximately 8,200 people worldwide. However, it's important to note that Bio-Rad's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.
What is Bio-Rad's revenue per employee?
$313,655. To calculate Bio-Rad's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.
What is the current stock price of Bio-Rad?
Currently, the price of one share of Bio-Rad stock is $295.73.
How can I analyze the BIO stock price chart for investment decisions?
The BIO stock price chart above provides a comprehensive visual representation of Bio-Rad's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Bio-Rad shares. Our platform offers an up-to-date BIO stock price chart, along with technical data analysis and alternative data insights.
Does BIO offer dividends to its shareholders?
As of our latest update, Bio-Rad (BIO) does not offer dividends to its shareholders. Investors interested in Bio-Rad should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Bio-Rad?
Some of the similar stocks of Bio-Rad are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.